These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17873184)

  • 41. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives.
    Bratel T; Lagerstrand L; Brodin LA; Nowak J; Randmaa I
    Chest; 2005 Dec; 128(6 Suppl):615S-616S. PubMed ID: 16373868
    [No Abstract]   [Full Text] [Related]  

  • 42. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 50-year-old woman with dyspnea, lower extremity edema, and volume loss of the right hemithorax.
    Shostak E; Sarwar A
    Chest; 2009 Aug; 136(2):628-632. PubMed ID: 19666764
    [No Abstract]   [Full Text] [Related]  

  • 46. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
    Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
    Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
    Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ
    Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous intravenous administration of a low dose of epoprostenol greatly decreased serum concentrations of endothelin-1 in primary pulmonary hypertension--a case report.
    Kakinuma Y; Honma S; Morimoto T; Maruyama H; Yamazaki A; Ishimitsu T; Yamaguchi I
    Angiology; 2005; 56(5):641-5. PubMed ID: 16193207
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Weight on Parenteral Prostacyclin Analogues Dosing in Pulmonary Hypertension.
    Raeisi-Giglou P; Wang XF; Dakkak W; Bair N; Dweik RA; Tonelli AR
    Chest; 2017 May; 151(5):1189-1192. PubMed ID: 28483121
    [No Abstract]   [Full Text] [Related]  

  • 50. Catastrophic circulatory collapse after inadvertent subcutaneous injection of treprostinil.
    Radosevich JJ; Dutt M; Feldman J
    Am J Health Syst Pharm; 2018 Jun; 75(11):768-772. PubMed ID: 29674328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.
    López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Barrios E; Vicente-Hernández M; Aguado JM; Escribano P
    Arch Bronconeumol; 2012 Dec; 48(12):443-7. PubMed ID: 22858303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapy for primary pulmonary hypertension.
    McCormack D
    Can Respir J; 2003 Apr; 10(3):169-70. PubMed ID: 12712230
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
    de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
    Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
    Reddy MT; Patel H; Ventura HO
    Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
    [No Abstract]   [Full Text] [Related]  

  • 55. Epoprostenol for very low birth weight (VLBW) infants: a novel dilution protocol.
    Rugolotto S; Beghini R; Cogo I; Sidoti G; Padovani EM; Pietrobelli A
    Pediatr Med Chir; 2013; 35(5):223-4. PubMed ID: 24516943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The globalization of clinical trials in pulmonary arterial hypertension.
    Park MH; Rubin LJ
    J Heart Lung Transplant; 2010 Feb; 29(2):157-8. PubMed ID: 20113908
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
    Barst RJ; Galie N; Naeije R; Simonneau G; Jeffs R; Arneson C; Rubin LJ
    Eur Respir J; 2006 Dec; 28(6):1195-203. PubMed ID: 16899485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin).
    Humbert M; Sanchez O; Fartoukh M; Jagot JL; Sitbon O; Simonneau G
    Chest; 1998 Jul; 114(1 Suppl):80S-82S. PubMed ID: 9676646
    [No Abstract]   [Full Text] [Related]  

  • 59. Patient safety challenges in treprostinil therapy.
    Roncesvalles A; Lee FW; Camamo J; Priestley G
    Medsurg Nurs; 2008 Apr; 17(2):101-6. PubMed ID: 18517170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertension.
    Desole S; Velik-Salchner C; Fraedrich G; Ewert R; Kähler CM
    Heart Lung; 2012; 41(6):599-605. PubMed ID: 22920608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.